Top Abstract Purchase Preview Related
Home
>
Node
>
Subnode

Management Decisions Made by Physician Assistants and Nurse Practitioners in Cutaneous Malignant Melanoma Patients: Impact of a 31-Gene Expression Profile Test

Mirsky, R.; Prado, G.; Svoboda, R.; Glazer, A.; Rigel, D.

Journal of drugs in dermatology JDD 17(11): 1220-1223

2018

ISSN/ISBN: 1545-9616
PMID: 30500144
Document Number: 17638
Importance: The 31 gene-expression profiling test (31-GEP) has been shown to provide useful prognostic information in patients with cutaneous melanoma. The test dichotomizes patients into lower risk (Class 1) or higher risk (Class 2) for melanoma metastasis. Previous studies have demonstrated the clinical utility of the test in impacting dermatologists' management decisions. Physician assistants and nurse practitioners (PA/NPs) account for a significant portion of dermatologic providers. The impact of a 31-GEP assay on clinical management has not been evaluated in this group.

Document emailed within 1 workday
Secure & encrypted payments

Management Decisions Made by Physician Assistants and Nurse Practitioners in Cutaneous Malignant Melanoma Patients: Impact of a 31-Gene Expression Profile Test

Farberg, A.S.; Glazer, A.M.; White, R.; Rigel, D.S. 2017: Impact of a 31-gene Expression Profiling Test for Cutaneous Melanoma on Dermatologists' Clinical Management Decisions Journal of Drugs in Dermatology: Jdd 16(5): 428-431
Valenti, W.M. 2006: Providing quality HIV care: role of nurse practitioners and physician assistants Aids Reader 16(5): 236-238
Coulter, I.; Jacobson, P.; Parker, L.E. 2000: Sharing the mantle of primary female care: physicians, nurse practitioners, and physician assistants Journal of the American Medical Women's Association 55(2): 100-103
Svoboda, R.M.; Glazer, A.M.; Farberg, A.S.; Rigel, D.S. 2018: Factors Affecting Dermatologists' use of a 31-Gene Expression Profiling Test as an Adjunct for Predicting Metastatic Risk in Cutaneous Melanoma Journal of Drugs in Dermatology: Jdd 17(5): 544-547
Rebeca, T.; Giselle, P.; Litchman, G.H..; Rigel, D.S.. 2019: Impact of Gene Expression Profile Testing on the Management of Squamous Cell Carcinoma by Dermatologists Journal of Drugs in Dermatology: Jdd 18(10): 980-984
Adam, Y.G.; Efron, G. 1983: Cutaneous malignant melanoma: current views on pathogenesis, diagnosis, and surgical management Surgery 93(4): 481-494
Trent, J.M.; Bittner, M.; Zhang, J.; Wiltshire, R.; Ray, M.; Su, Y.; Gracia, E.; Meltzer, P.; De Risi, J.; Penland, L.; Brown, P. 1997: Use of microgenomic technology for analysis of alterations in DNA copy number and gene expression in malignant melanoma Clinical and Experimental Immunology 107(Suppl): 33-40
Shannan, B.; Seifert, M.; Leskov, K.; Boothman, D.; Pföhler, C.; Tilgen, W.; Reichrath, J. 2006: Clusterin (CLU) and melanoma growth: CLU is expressed in malignant melanoma and 1,25-dihydroxyvitamin D3 modulates expression of CLU in melanoma cell lines in vitro Anticancer Research 26(4a): 2707-2716
Marghoob, A.A.; Kopf, A.W.; Rigel, D.S.; Bart, R.S.; Friedman, R.J.; Yadav, S.; Abadir, M.; Sanfilippo, L.; Silverman, M.K.; Vossaert, K.A. 1994: Risk of cutaneous malignant melanoma in patients with 'classic' atypical-mole syndrome. A case-control study Archives of Dermatology 130(8): 993-998
Queen, K.T. 2007: Use of nurse practitioners and physician extenders in rheumatology: a western North Carolina perspective North Carolina Medical Journal 68(6): 457-458
Gorelik, E.; Jay, G.; Kim, M.; Hearing, V.J.; DeLeo, A.; McCoy, J.P. 1991: Effects of H-2Kb gene on expression of melanoma-associated antigen and lectin-binding sites on BL6 melanoma cells Cancer Research 51(19): 5212-5218
Casazza, S.; Gambini, C.; Tunesi, G.; Rovida, S.; Caruso, F.; Pastorino, A.; Canepa, M. 1993: Expression of P53 protein in cutaneous melanoma Pathologica 85(1097): 335-342
Jelfs, P.L.; Giles, G.; Shugg, D.; Coates, M.; Durling, G.; Fitzgerald, P.; Ring, I. 1994: Cutaneous malignant melanoma in Australia, 1989 Medical Journal of Australia 161(3): 182-187
Al-Shlash, S.; al-Shareef, Z.; Jaber, K.; al Hoquail; Somorin, A. 1998: Cutaneous malignant melanoma: Tabuk experience African Journal of Medicine and Medical Sciences 27(1-2): 85-88
Vile, R.G.; Nelson, J.A.; Castleden, S.; Chong, H.; Hart, I.R. 1994: Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component Cancer Research 54(23): 6228-6234
Melia, J. 1997: Changing incidence and mortality from cutaneous malignant melanoma Bmj 315(7116): 1106-1107
Stella, C.; Cerroni, L.; Pecorella, I.; Ciardi, A.; Renda, F.; Battistelli, S.; Stella, F.; Troccoli, R. 1985: Multiple breast metastasis of cutaneous malignant melanoma Annali Italiani di Chirurgia 57(5): 441-445
Maillard, G.F. 1971: Statistical study of 623 cases of malignant cutaneous melanoma Annales de Dermatologie et de Syphiligraphie 98(1): 5-20
Ma, C.; Stimpfel, A.Witkoski. 2018: The Association Between Nurse Shift Patterns and Nurse-Nurse and Nurse-Physician Collaboration in Acute Care Hospital Units Journal of Nursing Administration 48(6): 335-341
Miura, T.; Ishikawa, S. 1970: Malignant melanoma--synopses from the seminar on malignant melanoma by International Group for the Clinical Study of Melanoma Gan no Rinsho. Japan Journal of Cancer Clinics 16(11): 1064-1070